Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications selecting chronic constipation cc clinical trial endpoints incorporating patients voice
… 2022). Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2). Spira A, Zhou X, Liao L, Yu E, Chen L, Lau …
… MSBase Registry: Comparing Natalizumab to Fingolimod in Patients with Inadequate Response to Disease-Modifying … data from the international MSBase registry we studied the clinical effectiveness of switching to natalizumab for … analyses for both Italy and Spain, these clinical benefits translated to higher quality-adjusted …
… provides guidance to manufacturers regarding communicating clinical and economic evidence to support new products or new … Another may view it as an opportunity to present as much clinical data as early as possible. These objectives may also … the inclusion of clinical data affect planned or pending publications? Manufacturers should determine the appropriate …
… Multiple sclerosis Overactive bladder Pain (acute and chronic) Parkinson’s Restless legs syndrome Sleep Stroke …
… of disease frequency Risk factors and comorbidities Clinical practice patterns Utilization and persistence Drug … Example Brief disease backgrounder for use in planning clinical development programs. Incidence of adverse events …
… estimating budget impact: Estimating the target population Selecting a time horizon Identifying current and projected … This class illustrates that you really have to apply your clinical knowledge and assess the information critically to …
… developers prepare for making their products available to patients and providers, navigating the HTA process can be a …
… to healthcare payers, regulators, providers, and patients. Who can benefit from early market access planning …
… of Loncastuximab Tesirine in older versus younger patients with relapsed/refractory diffuse Large b-cell lymphoma treated in a phase 2 clinical trial (LOTIS-2). Poster …
… and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large B-cell lymphoma treated in a phase 2 clinical trial (LOTIS 2). Spira A, Liao L, Zhou X, Gnanasakthy A, Chen …